According to a recent LinkedIn post from Aignostics, the company is promoting a new initiative called Atlas for Academics that makes its Atlas H&E-TME tumor microenvironment profiling application freely available to academic researchers. The post outlines two components: OpenTME, an open-access dataset of TCGA whole-slide images analyzed with Atlas H&E-TME, and a Research Access Program allowing institutions to run their own H&E slides at no cost.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Aignostics is using free academic access to expand adoption and validation of its AI pathology platform within the research community. For investors, broader academic usage could help strengthen the evidence base, drive future clinical or biopharma partnerships, and create long-term funnel effects for commercial demand, although near-term direct revenue impact from this initiative appears limited.